Cardiovascular Systems - CSII Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CSII shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CSII, but not buy additional shares or sell existing shares.
View CSII analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month price objectives for Cardiovascular Systems' shares. Their CSII share price forecasts range from $20.00 to $40.00. On average, they anticipate the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 114.1% from the stock's current price.
View analysts price targets for CSII or view top-rated stocks among Wall Street analysts.

Cardiovascular Systems' stock was trading at $18.78 at the beginning of 2022. Since then, CSII shares have decreased by 25.4% and is now trading at $14.01.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CSII earnings forecast.

Cardiovascular Systems, Inc. (NASDAQ:CSII) issued its quarterly earnings results on Monday, November, 8th. The medical device company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.12. The medical device company had revenue of $58.40 million for the quarter, compared to the consensus estimate of $63.72 million. Cardiovascular Systems had a negative net margin of 15.64% and a negative trailing twelve-month return on equity of 14.40%. The firm's quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.05) earnings per share.

Cardiovascular Systems issued an update on its FY 2023 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $255.00 million-$265.00 million, compared to the consensus revenue estimate of $236.73 million.

35 employees have rated Cardiovascular Systems Chief Executive Officer Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among the company's employees. 83.0% of employees surveyed would recommend working at Cardiovascular Systems to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Procter & Gamble (PG).

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Shares of CSII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSII stock can currently be purchased for approximately $14.01.

Cardiovascular Systems (NASDAQ:CSII) has a market capitalization of $573.99 million and generates $236.22 million in revenue each year. The medical device company earns $-36,930,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

The company employs 780 workers across the globe.

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The official website for the company is www.csi360.com. The medical device company can be reached via phone at (651) 259-1600, via email at j.nielsen@csi360.com, or via fax at 612-677-3355.